Please assess the completion status of the following clinical trial:

Trial Title: Ramipril in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with rheumatoid arthritis (4 out of 7 ARA criteria must be fulfilled to establish diagnosis) on stable background therapy for the last three months~* endothelial dysfunction (FMD \< 4%, FMD:Flow-Mediated-Dilatation)~* non-smokers~Exclusion Criteria:~* previous myocardial infarction, coronary intervention or coronary surgery~* previous treatment with statins in the last 6 months~* previous treatment with ACE-inhibitors in the last 6 months~* uncontrolled hypertension SAP/DAP \> 160/90 mmHg (SAP:Systolic Arterial Pressure, DAP:Diastolic Arterial Pressure)~* dyslipidemia (LDL-cholesterol \> 4.9 mmol)~* normal CRP \< 3 mg/l~* overweight BMI \> 35kg/m2~* anaemia (hemoglobin \< 10g/dl)~* kidney disease (creatinine \> 150 umol/l)~* insulin-dependent diabetes mellitus~* congestive heart failure (\> NYHA I)~* AV-Block\>I~* pregnancy~* angio-edema~* malignancy or chronic infection~* drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).